Latest News and Press Releases

LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and...

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

Previous interim results showing strong safety and potent immunogenicity support trial expansion and advancement of ACI-35.030 into Phase 2b/3 Alternative vaccine candidate also advances to...

Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3Initiated first-in-human clinical study...

Dr. Colowick has more than 20 years of experience in large and emerging biotech companies Led investments for several clinical-stage companies as a Partner at Sofinnova Investments LAUSANNE,...

LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will...

Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases Webinar will take place on Wednesday, March 31, 2020 at 10:00 AM ET ...

Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3 Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b...

Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium Reported new data in non-human primates for optimized vaccine formulation which shows...